This gain-of-function mutation in LRRK2 has been associated with a higher risk of PD, and consequently LRRK2 inhibitors have been pursued as a potential avenue for PD treatment (Zhao and Dzamko, 2019). The gene discussed is LRRK2; the disease is Parkinson disease.